Company intelligence / Profile preview

PharmatrophiX, Inc.

Menlo Park/San Francisco*, California, United Statespharmatrophix.com ↗
Ownership
Private
Development stage
Clinical
01

Overview

PharmatrophiX has advanced its lead candidate LM11A‑31, a p75NTR ligand, into Phase 1 and subsequently Phase 2 trials for Alzheimer’s disease. The compound demonstrated safety in healthy volunteers and elderly subjects in Phase 1. Preclinical data show efficacy in animal models of Alzheimer’s disease by inhibiting tau phosphorylation and synaptic degeneration. Additional programs targeting TrkB/TrkC are at the preclinical stage.

Therapeutic areas
Neurology
Modalities
small molecules
Industry
Biotech
02

Drug pipeline

3 assets

LM11A-31

2

2 more assets in the full pipeline.

Request access →
03

Partnerships

No major pharmaceutical partnerships publicly disclosed; prior funding from private investors and peer-reviewed grants including the Alzheimer’s Drug Discovery Foundation.

Beyond the preview

Go deeper on PharmatrophiX, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmatrophiX, Inc..

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call